The Hypoparathyroidism drugs in development market research report provides comprehensive information on the therapeutics under development for Hypoparathyroidism, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Hypoparathyroidism. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Hypoparathyroidism and features dormant and discontinued products.

GlobalData tracks 13 drugs in development for Hypoparathyroidism by 13 companies/universities/institutes. The top development phase for Hypoparathyroidism is preclinical with six drugs in that stage. The Hypoparathyroidism pipeline has 13 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Hypoparathyroidism pipeline products market are: Entera Bio, ProLynx and Shandong Buchang Pharmaceutical.

The key targets in the Hypoparathyroidism pipeline products market include Parathyroid Hormone/Parathyroid Hormone Related Peptide Receptor (PTH/PTHrP Type I Receptor or Parathyroid Hormone 1 Receptor or PTH1R), Parathyroid Hormone Receptor, and Parathyroid Hormone 2 Receptor (PTH2R).

The key mechanisms of action in the Hypoparathyroidism pipeline product include Parathyroid Hormone/Parathyroid Hormone Related Peptide Receptor (PTH/PTHrP Type I Receptor or Parathyroid Hormone 1 Receptor or PTH1R) Agonist with six drugs in Filing rejected/Withdrawn. The Hypoparathyroidism pipeline products include three routes of administration with the top ROA being Subcutaneous and six key molecule types in the Hypoparathyroidism pipeline products market including Recombinant Peptide, and Small Molecule.

Hypoparathyroidism overview

Hypoparathyroidism is decreased function of the parathyroid glands with underproduction of parathyroid hormone. This leads to low levels of calcium in the blood, often causing cramping and twitching of muscles (involuntary muscle contraction) and several other symptoms. The condition can be inherited, but it is also encountered after thyroid or parathyroid gland surgery, and it can be caused by immune system-related damage as well as a number of rarer causes. The treatment includes an artificial form of the hormone that can be administered as replacement, calcium replacement, or vitamins.

For a complete picture of Hypoparathyroidism’s pipeline drug market, buy the report here.

This content was updated on 25 January 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.